Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Health technology assessors

Kidney cancer drug to be funded by NHS after manufacturer cuts price

Everolimus has been recommended for use in the NHS by the National Institute for Health and Care Excellence after its manufacturer, Novartis, cuts its price.

The health technology assessment body’s decision comes in a draft guidance, published on 12 January 2017, which recommends the drug for some patients with advanced renal cell carcinoma (RCC).

Everolimus, which is branded as Afinitor, was originally available through the cancer drugs fund (CDF) but following Novartis’ price discount and consideration of new evidence, NICE has now recommended that it is routinely available on the NHS. The drug will be available through a patient access scheme.

The discount is confidential, but a year’s treatment cost around £32,000 per patient before the discount.

Given as an oral tablet (10mg once a day), the drug is an active inhibitor of the mammalian target of rapamycin (mTOR) protein, which is a central regulator of tumour cell division and blood vessel growth in cancer cells.

NICE says treatment should continue as long as there is clinical benefit or until there are unacceptable adverse events, adding that management of severe adverse events may need dose reduction to 5mg daily or temporary withholding of everolimus.

Carole Longson, director of the centre for health technology evaluation at NICE

Source: NICE

Carole Longson, director of the centre for health technology evaluation at NICE, says Novartis demonstrated that renal cancer treatment everolimus was cost effective

Carole Longson, director of the centre for health technology evaluation at NICE, says: “Advanced renal cell carcinoma is a relatively rare cancer and unfortunately there are limited treatment options for this condition.

“The company engaged positively with the process of reconsidering drugs in the CDF, demonstrated their drug to be cost effective, and as such we were pleased to make a positive recommendation,” she adds. “This decision, when implemented, will allow funding in the CDF to be freed up, which can then be spent on other new and innovative cancer treatments.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202186

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • Prescribing Medicines for Children

    Prescribing Medicines for Children

    Prescribing Medicines for Children is designed to improve understanding on all aspects of paediatric prescribing, from the development of suitable drugs through to their practical administration.

    £60.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Carole Longson, director of the centre for health technology evaluation at NICE

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.